CN114099608A - Anti-virus and anti-bacterial traditional Chinese medicine composition containing calcite and preparation method and application thereof - Google Patents
Anti-virus and anti-bacterial traditional Chinese medicine composition containing calcite and preparation method and application thereof Download PDFInfo
- Publication number
- CN114099608A CN114099608A CN202010884299.7A CN202010884299A CN114099608A CN 114099608 A CN114099608 A CN 114099608A CN 202010884299 A CN202010884299 A CN 202010884299A CN 114099608 A CN114099608 A CN 114099608A
- Authority
- CN
- China
- Prior art keywords
- parts
- antibacterial
- antiviral
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 229910021532 Calcite Inorganic materials 0.000 title abstract description 7
- 230000002155 anti-virotic effect Effects 0.000 title description 3
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 64
- 239000002994 raw material Substances 0.000 claims abstract description 29
- 208000024891 symptom Diseases 0.000 claims abstract description 23
- 241000605372 Fritillaria Species 0.000 claims abstract description 19
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 18
- 239000010440 gypsum Substances 0.000 claims abstract description 18
- 241001529821 Agastache Species 0.000 claims abstract description 17
- 241000222336 Ganoderma Species 0.000 claims abstract description 17
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 14
- 239000010231 banlangen Substances 0.000 claims abstract description 14
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 13
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 13
- 206010068319 Oropharyngeal pain Diseases 0.000 claims abstract description 12
- 240000004980 Rheum officinale Species 0.000 claims abstract description 11
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 11
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 10
- 208000002193 Pain Diseases 0.000 claims abstract description 9
- 230000001754 anti-pyretic effect Effects 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 15
- 241001162994 Rugosus Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 241000951473 Schizonepeta Species 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 241000219061 Rheum Species 0.000 claims description 6
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 240000004510 Agastache rugosa Species 0.000 claims description 4
- 241000207929 Scutellaria Species 0.000 claims description 3
- 239000002221 antipyretic Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 244000236521 Bupleurum rotundifolium Species 0.000 claims description 2
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 claims description 2
- 241000576429 Forsythia suspensa Species 0.000 claims description 2
- 229940124350 antibacterial drug Drugs 0.000 claims description 2
- 208000023409 throat pain Diseases 0.000 claims description 2
- 208000001387 Causalgia Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 19
- 241001465754 Metazoa Species 0.000 abstract description 15
- 238000002474 experimental method Methods 0.000 abstract description 6
- 239000011248 coating agent Substances 0.000 abstract description 4
- 238000000576 coating method Methods 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 29
- 210000004072 lung Anatomy 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 239000012085 test solution Substances 0.000 description 9
- 241000555712 Forsythia Species 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- 235000015278 beef Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 241000334160 Isatis Species 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000202726 Bupleurum Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000000312 effect on influenza Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000021259 spicy food Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000951376 Schizonepeta tenuifolia Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000799 cathartic agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, in particular to an antiviral and antibacterial traditional Chinese medicine composition containing calcite and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials: fructus forsythiae, herba schizonepetae, radix isatidis, scutellaria baicalensis, herba agastaches, gypsum rubrum, radix bupleuri, rheum officinale, fritillaria and lucid ganoderma. The antiviral composition can effectively cure symptoms of dry stool, fever, fantod, burning pain of skin, sore throat, thin and yellow tongue coating, red tongue and rapid pulse caused by internal heat, and animal experiments and antibacterial experiments prove that the antibacterial and antiviral traditional Chinese medicine composition has remarkable antiviral, antibacterial and antipyretic effects, so that the antiviral and antiviral traditional Chinese medicine composition can be prepared into medicines for treating the symptoms and antiviral and antibacterial medicines.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to an antiviral and antibacterial traditional Chinese medicine composition containing calcite and a preparation method and application thereof.
Background
Modern people have fast pace of life, irregular work and rest, and the symptoms of 'excessive internal heat', such as dry stool, fever of the whole body, sore throat and the like, are easy to appear after long-term accumulation. The western medicine aims at the symptoms, such as cathartic or probiotics are adopted to relieve constipation, antipyretic or physical ways are adopted to lower the temperature, and anti-inflammatory drugs and antibiotics are used to treat sore throat, but the symptoms can only be treated, the root cause cannot be treated, the treatment effect is poor, and the symptoms still relapse after the medicine is stopped. Especially dry stool, probiotics has slow effect and weak curative effect, and cathartics may cause drug dependence, and long-term use may reduce enterokinesia function to aggravate symptoms.
From the perspective of traditional Chinese medicine, the above "internal heat" symptoms are caused by imbalance of yin and yang and vigorous internal fire, i.e., internal heat. The traditional Chinese medicine with reasonable formula can achieve the treatment effect of treating both symptoms and root causes, and can avoid the problems of western medicines. However, the monarch, minister, assistant and guide relationships exist among the medicinal ingredients of the traditional Chinese medicine formula, and if the Chinese medicinal ingredients are not matched properly, the ideal treatment effect cannot be achieved. For example, if the herb flavor of sweating to counteract exterior is mistakenly used to abate fever, it is not only difficult to dispel exterior heat, but also can make internal heat more beneficial and aggravate the symptoms.
Disclosure of Invention
Aiming at the technical problems that the curative effect of western medicines for treating internal heat symptoms is poor, the traditional Chinese medicines are not matched properly and the ideal treatment effect is difficult to achieve at present, the invention provides an anti-virus and anti-bacterial traditional Chinese medicine composition containing calcite and a preparation method and application thereof.
In order to achieve the purpose of the invention, the embodiment of the invention adopts the following technical scheme:
on one hand, the embodiment of the invention provides an antibacterial and antiviral traditional Chinese medicine composition which comprises the following raw materials in parts by weight: 8-13 parts of fructus forsythiae, 6-12 parts of herba schizonepetae, 12-18 parts of radix isatidis, 7-12 parts of scutellaria baicalensis, 7-12 parts of agastache rugosus, 7-12 parts of gypsum rubrum, 6-11 parts of radix bupleuri, 2-4 parts of rheum officinale, 6-12 parts of fritillaria and 4-8 parts of lucid ganoderma.
The antibacterial and antiviral traditional Chinese medicine composition provided by the invention comprises the following components:
forsythia fruit, fructus forsythiae, with slightly cold nature, enters lung, heart and gallbladder meridians, is good at clearing heat and removing toxicity, especially clearing heart fire to disperse wind-heat in upper energizer, and also can cure abscess and dissipate nodulation.
Schizonepeta has mild property and mild property, enters lung and liver meridians, and can disperse and promote eruption, dispel wind and release exterior, relieve itching and stop bleeding.
Radix Isatidis, being cold in nature, enters heart and stomach meridians, and is good at clearing excess heat and fire toxin, cooling blood and relieving sore throat, and dispersing swelling and dissipating stagnation.
Baikal skullcap root, with cold nature, enters lung, gallbladder, stomach and large intestine meridians, has the actions of clearing heat and drying dampness, purging fire and removing toxicity, is good at clearing lung and large intestine fire, especially clearing lung heat, and removing damp-heat in stomach intestine, liver and gallbladder, and enters blood system, so it can clear heat, cool blood and stop bleeding.
Agastache rugosus has mild warm property, enters spleen, stomach and lung meridians, has warm nature and is not dry, can not only harmonize the middle energizer and damp-turbidity of spleen and stomach, but also harmonize the middle warmer and arrest vomiting, and can disperse exterior cold.
Cold water stone is cold in nature, enters heart, stomach and kidney meridians, clears heat and lowers fire, detoxifies, benefits orifices and reduces swelling.
Radix bupleuri is slightly cold in nature, enters heart and liver meridians, gallbladder meridians and triple energizer meridians, disperses and reduces fever, soothes liver and relieves depression, raises yang and holds down the sinew, and harmonizes exterior and interior.
Rhubarb, being cold in nature, enters spleen, stomach, large intestine, liver and pericardium channels, has the property of sinking, can lead heat to descend, has strong purgative effect, can purge and eliminate accumulation, wash intestines and stomach, and clear heat of blood components, and has the effects of cooling blood, removing toxicity, activating blood and removing stasis.
Fritillaria is slightly cold in nature, enters lung, stomach, spleen and heart meridians, and has effects of clearing heat, moistening lung, eliminating phlegm, relieving cough, resolving hard mass and resolving carbuncle.
Ganoderma lucidum is neutral in nature, enters liver, lung and kidney channels, replenishes qi and blood, calms mind, strengthens spleen and stomach, relieves cough and asthma, and tonifies and strengthens.
When yang-qi turns to internal heat, the body fluids in the intestine are deficient, so the stool is dry and hard to descend, causing dysphoria with smothery sensation. The lung and the large intestine are exterior-interior and not descending, so that the lung qi is obstructed, and stagnated heat causes lung fullness, burning pain of skin and sore throat. The lung governs the skin and hair, and the throat is the portal of the lung and stomach, and yin deficiency of the lung and stomach makes the gate closed unfavorably. In the antibacterial and antiviral traditional Chinese medicine composition, the rhubarb is bitter and cold, accumulates food in the lower part, leads to diuresis and removes intestines and stomach; stone chilly, pungent and cold in property, fever, restlessness and burning pain of skin; forsythia fruit, fructus forsythiae, bitter in flavor and mild in flavor, is mainly responsible for the accumulation of heat and abscess. The three medicines are combined to be a monarch medicine. Radix isatidis, scutellaria baicalensis and fritillaria are used as ministerial drugs to assist the monarch drug in treating the upper-jiao fever; radix bupleuri, herba schizonepetae and wrinkled gianthyssop are used, the pungent and warm medicinal ingredients are taken, the cold and cool medicinal ingredients are used for dispelling wind and heat, and the lucid ganoderma is used for strengthening body resistance and improving the immunity.
Clinical application effects prove that the whole formula can effectively cure symptoms of dry stool, fever, fantod, burning pain of skin, sore throat, thin and yellow tongue coating, red tongue and rapid pulse through the compatibility of the medicines. Animal experiments and bacteriostatic experiments prove that the antibacterial and antiviral traditional Chinese medicine composition has remarkable antiviral, antibacterial and antipyretic effects.
Preferably, the antibacterial and antiviral traditional Chinese medicine composition comprises the following raw materials in parts by weight: 9-12 parts of fructus forsythiae, 7-10 parts of herba schizonepetae, 13-16 parts of radix isatidis, 8-11 parts of scutellaria baicalensis, 8-11 parts of agastache rugosus, 8-11 parts of gypsum rubrum, 7-10 parts of radix bupleuri, 2-4 parts of rheum officinale, 7-10 parts of fritillaria and 5-7 parts of lucid ganoderma.
Preferably, the antibacterial and antiviral traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10 parts of fructus forsythiae, 9 parts of herba schizonepetae, 15 parts of radix isatidis, 10 parts of scutellaria baicalensis, 9 parts of agastache rugosus, 9 parts of gypsum rubrum, 9 parts of radix bupleuri, 3 parts of rheum officinale, 9 parts of fritillaria and 6 parts of lucid ganoderma.
In the practical use of the traditional Chinese medicine, 1g of the traditional Chinese medicine is used as each dose, and 1-2 doses are used every day according to the state of illness.
In a second aspect, the embodiment of the present invention further provides a preparation method of the antibacterial and antiviral traditional Chinese medicine composition, including the following operations: weighing the raw materials according to the raw material proportion in the antibacterial and antiviral traditional Chinese medicine composition, extracting volatile oil of the wrinkled gianthyssop herb, decocting residues with the weeping forsythia, the fineleaf schizonepeta herb, the indigowoad root, the baical skullcap root, the gypsum rubrum, the Chinese thorowax root, the rhubarb, the fritillaria and the lucid ganoderma in water, extracting, filtering, collecting obtained filtrate, and drying to obtain a water-decocted extract; and adding the volatile oil of the agastache rugosus into the obtained water decoction extract, and uniformly mixing to obtain the antibacterial and antiviral traditional Chinese medicine composition. The product prepared by the preparation method can be further processed into oral dosage forms such as tablets, granules, powder, capsules, syrup, suspension, big honeyed pills and the like according to the actual needs of clinical use or dosage form requirements.
Wherein, the water-decocted extract can be prepared by the following operation processes: weighing the raw materials according to the raw material ratio in the antibacterial and antiviral traditional Chinese medicine composition, decocting the gypsum for 15-25 min, adding the residue after the volatile oil is extracted from the agastache rugosus and the forsythia, the schizonepeta, the isatis root, the scutellaria baicalensis, the gypsum rubrum, the bupleurum, the fritillaria and the lucid ganoderma, decocting, adding the rheum officinale, continuing to decoct for 5-10 min, filtering to obtain a water-decocted filtrate, and drying the water-decocted filtrate to obtain a water-decocted extract. The water amount for decocting the gypsum is preferably 6-9 times of the total weight of the fructus forsythiae, the herba schizonepetae, the radix isatidis, the radix scutellariae, the gypsum rubrum, the radix bupleuri, the fritillaria and the lucid ganoderma, and the fructus forsythiae, the herba schizonepetae, the radix isatidis, the radix scutellariae, the gypsum rubrum, the radix bupleuri, the fritillaria and the lucid ganoderma are directly added to be decocted for 2-3 times, 20-35 min each time, preferably 2 times, and 30min each time. The time for decocting is preferably 8min after adding radix et rhizoma Rhei.
The drying method in the preparation method can adopt a spray drying or decompression drying method at 45-55 ℃, or freeze drying, and before drying, decompression concentration at 45-55 ℃ can be carried out.
In a third aspect, the embodiment of the invention also provides application of the antibacterial and antiviral traditional Chinese medicine composition in preparing a medicine for treating dry stool.
In a fourth aspect, the embodiment of the invention also provides application of the antibacterial and antiviral traditional Chinese medicine composition in preparing an antipyretic.
In a fifth aspect, the embodiment of the invention also provides application of the antibacterial and antiviral traditional Chinese medicine composition in preparing a medicine for treating burning pain of skin.
In a sixth aspect, the embodiment of the invention also provides application of the antibacterial and antiviral traditional Chinese medicine composition in preparing a medicine for treating throat pain.
In a seventh aspect, the embodiment of the invention also provides an application of the antibacterial and antiviral traditional Chinese medicine composition in preparing a medicine for treating at least two symptoms of dry stool, fever, burning pain of skin and sore throat.
Clinical verification shows that the antibacterial and antiviral traditional Chinese medicine composition has obvious treatment effects on dry stool, fever, fantod, burning pain of skin, sore throat, thin and yellow tongue coating, red tongue and rapid pulse caused by internal heat of yangming and insufficient body fluid of intestinal tract, so that the antibacterial and antiviral traditional Chinese medicine composition can be used for preparing medicines for treating one or more symptoms.
In an eighth aspect, the embodiment of the present invention further provides an antiviral and/or antibacterial drug, which includes the above antibacterial and antiviral traditional Chinese medicine composition.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. The experimental procedures used in the following examples are all conventional in the art unless otherwise specified.
The forsythia, schizonepeta, isatis root, scutellaria, agastache, gypsum rubrum, bupleurum, rhubarb, fritillaria and ganoderma lucidum used in the following examples all meet the relevant regulations under each medicinal material item in the text of the Chinese pharmacopoeia (2015 edition).
The raw materials, reagents and the like used in the following examples were obtained commercially unless otherwise specified.
Examples
The embodiment of the invention provides an antibacterial and antiviral traditional Chinese medicine composition, and the raw material composition of each dose is shown in table 1 (unit: g) in each embodiment.
TABLE 1 raw material composition of the antibacterial and antiviral Chinese medicinal composition of each example
| Raw materials | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 |
| Forsythia fruit | 10 | 9 | 12 | 8 | 13 |
| Schizonepeta tenuifolia | 9 | 7 | 10 | 6 | 12 |
| Radix Isatidis | 15 | 13 | 16 | 12 | 18 |
| Radix Scutellariae | 10 | 8 | 11 | 7 | 12 |
| Agastache rugosus | 9 | 8 | 11 | 7 | 12 |
| Gypsum Fibrosum | 9 | 8 | 11 | 7 | 12 |
| Radix bupleuri | 9 | 7 | 10 | 6 | 11 |
| Radix et rhizoma Rhei | 3 | 2 | 4 | 2 | 4 |
| Fritillaria | 9 | 7 | 10 | 6 | 12 |
| Glossy ganoderma | 6 | 5 | 7 | 4 | 8 |
The embodiment of the invention also provides a preparation method of the antibacterial and antiviral traditional Chinese medicine composition in the embodiment, the raw materials are weighed according to the raw material proportion in the antibacterial and antiviral traditional Chinese medicine composition in the embodiment, volatile oil of agastache rugosus is extracted, gypsum is decocted for 15-25 min, residues obtained after volatile oil extraction of the agastache rugosus, forsythia, schizonepeta, isatis root, scutellaria baicalensis, gypsum rubrum, radix bupleuri, fritillaria and lucid ganoderma are added, and the mixture is decocted for 2-3 times, 20-35 min each time; then adding rhubarb and continuing to decoct for 5-10 min, filtering to obtain a water-decocted filtrate, and spray-drying the water-decocted filtrate at 45-55 ℃ to obtain a water-decocted extract; adding herba Agastaches volatile oil into the obtained water decoction extract, and mixing.
The specific parameters and conditions of the preparation process of each example are shown in table 2.
TABLE 2 preparation parameters of the examples
Comparative example 1
The invention provides an antibacterial and antiviral traditional Chinese medicine composition, which is based on the raw material composition of example 1, and the rheum officinale with similar efficacy to the calcite and capable of clearing heat and purging fire is increased by removing the calcite. The raw materials in each dose are: 10g of fructus forsythiae, 9g of herba schizonepetae, 15g of radix isatidis, 10g of scutellaria baicalensis, 9g of agastache rugosus, 9g of radix bupleuri, 12g of rheum officinale, 9g of fritillaria and 6g of lucid ganoderma. The preparation method is the same as example 1.
Comparative example 2
The invention provides an antibacterial and antiviral traditional Chinese medicine composition, which is prepared by taking the raw material composition of example 1 as a basis, removing forsythia, and increasing the using amount of radix isatidis which has similar efficacy with forsythia and can clear away heat and toxic materials. The raw materials in each dose are: 9g of schizonepeta, 25g of isatis root, 10g of scutellaria baicalensis, 9g of wrinkled gianthyssop herb, 9g of gypsum rubrum, 9g of radix bupleuri, 3g of rheum officinale, 9g of fritillaria and 6g of lucid ganoderma. The preparation method is the same as example 1.
Effect example 1
The effect example provides a mouse gavage single-administration toxicity test of the antibacterial and antiviral traditional Chinese medicine composition, so as to observe possible toxic reaction after the antibacterial and antiviral traditional Chinese medicine composition is taken.
1. Material
1.1 test drugs
The test solutions were prepared according to the methods and the raw materials of examples 1 to 5, respectively, by uniformly grinding, dissolving with 0.5% CMC-Na, and preparing to a concentration of 2.2g crude drug/ml.
1.2 test animals
ICR mice, SPF grade, 240 mice, 20-22g, half male and half female, purchased from Beijing Wintonlihua laboratory animal technology Co., Ltd, license number: SCXK (Kyoto) 2016-.
2. Method of producing a composite material
2.1 grouping and administration
The male and female mice were randomly divided into 6 groups of 20 mice each, and each group was a blank control group and 5 example groups (example 1 group, example 2 group, example 3 group, example 4 group and example 5 group), each example group was gavaged with the test solutions of examples 1 to 5 obtained in 1.1, respectively, at a volume of 0.4ml/10g body weight (maximum volume), and were co-administered twice a day at 6-hour intervals, and the blank control group was administered with an equal amount of 0.5% CMC-Na. All animals were fasted overnight before dosing without water deprivation.
2.2 observed metrics, time and content
After each administration, the animals are continuously observed for 2 hours, and the animals are observed for physical signs, behaviors, secretions, excretions, death conditions, toxic reactions (symptoms, initial time, severity, duration and reversibility of toxic reactions) and the like, and the information of the appearance time, duration and the like of abnormal symptoms is recorded in detail. Animal body weight and food intake were recorded once a day on days 1, 2, 3, 4, 7, and 14 after dosing for 14 consecutive days. At the end of the observation period, the surviving animals were euthanized, gross dissected, and when changes in organ volume, color, texture, etc. were found, histopathological examination of the altered organs was performed.
2.3 data analysis
The test data adopts SPSS18.0 statistical software, and the results are mean plus or minus standard deviation
Indicated, independent sample two-sided T-test was used.
3. Results
3.1 Effect on general conditions
The blank control group and each example group have no abnormal general condition observation.
3.2 Effect on body weight and food intake
Compared with the blank control group, the weights of the female animals and the male animals in each example group are not obviously and statistically different; the food intake was not significantly different from that of the blank control group. See tables 3-6.
TABLE 3 ICR mice gavage Single dose toxicity test Male body weight Change
(g)
TABLE 4 weight change in female animals tested for toxicity in ICR mice by single gavage administration
(g)
TABLE 5 ICR mice gavage Single dose toxicity test Male intake Change
(g/day/only)
TABLE 6 ICR mice gavage Single dose toxicity test female animals intake Change
(g/day/only)
3.3 general dissection
After the observation period, the mice of the blank control group and the mice of the examples are roughly dissected, and no obvious abnormality is found in the heart, the liver, the spleen, the lung, the kidney, the brain, the stomach, the intestine, the thymus, the reproductive organs, the bladder and the like.
4. Conclusion
The maximum dose of the mouse gavage drug is 176g crude drug/kg, and no related toxic reaction of the test substance is found at the dose.
Effect example 2
The effect example provides an experiment on the influence of the antibacterial and antiviral traditional Chinese medicine composition on the fever of rats caused by LPS, so as to observe the antipyretic effect of taking the antibacterial and antiviral traditional Chinese medicine composition.
1. Material
1.1 test drugs
The test solutions were prepared according to the raw material compositions and preparation methods of examples 1 to 5 and comparative examples 1 and 2, respectively, by uniformly grinding, dissolving with 0.5% CMC-Na, and formulating to a concentration of 0.3g crude drug/ml as a test solution.
1.2 test animals
SD rat, SPF grade, 96, 180-: SCXK (Kyoto) 2016-.
2. Method of producing a composite material
2.1 grouping and administration
Rats were randomly divided into 8 groups of 12 rats each, which were a model control group, 5 example groups (example 1 group, example 2 group, example 3 group, example 4 group and example 5 group), a comparative example 1 group and a comparative example 2 group, respectively, each example group was gavaged with the test solutions of examples 1 to 5 obtained in 1.1, and each comparative example 1 group and comparative example 2 group was gavaged with the test solutions of comparative examples 1 and 2 obtained in 1.1, respectively, with a gavage volume of 1ml/100g body weight. The model control group was given an equivalent amount of 0.5% CMC-Na. 30min after each group of rats is dosed, anal temperature is measured once and recorded as T0Then, 20. mu.g/kg LPS (saline solution preparation) was intraperitoneally injected to make a mold, and the volume was 5 ml/kg. After the model is made, the anal temperature is measured every 1h and recorded as TxContinuously calculating the temperature difference delta T of the body for 5h, wherein the delta T is equal to Tx-T0。
2.2 data analysis
The test data adopts SPSS18.0 statistical software, and the results are mean plus or minus standard deviation
Showing that one-way analysis of variance is adopted.
3. Results
The temperature difference of the rat body of the model control group is obviously increased after 1-5h of intraperitoneal LPS (Low pressure) injection molding, compared with the model control group, the temperature difference of the rat body of the example group is obviously reduced after 2h and 3h of molding (P <0.05), and the temperature difference of the rat body of the comparative group is obviously reduced after 3h of molding (P < 0.05). See table 7.
TABLE 7 Effect on LPS induced fever in rats
Note: comparison with model control group: p < 0.05.
4. Conclusion
The antibacterial and antiviral traditional Chinese medicine composition provided by the invention has the effect of inhibiting fever caused by rat intraperitoneal injection of LPS, and the antibacterial and antiviral traditional Chinese medicine composition provided by the embodiment of the invention is superior to a comparative example.
Effect example 3
The effect example provides the influence of the antibacterial and antiviral traditional Chinese medicine composition on influenza virus pneumonia of mice so as to observe the antiviral effect of taking the antibacterial and antiviral traditional Chinese medicine composition.
1. Material
1.1 test drugs
The test solutions were prepared according to the raw material compositions and preparation methods of examples 1 to 5 and comparative examples 1 and 2, respectively, by uniformly grinding, dissolving with 0.5% CMC-Na, and formulating to a concentration of 0.44g crude drug/ml as a test solution.
1.2 test animals
KM mice, SPF grade, 108, 20-22g, male, purchased from experimental animal technology ltd, viton, beijing, license number: SCXK (Kyoto) 2016-.
1.3 viruses
Influenza virus mouse lung adapted strain (FM)1) It is introduced from virology research institute of Chinese academy of preventive medicine science, and is used by inoculating allantoic cavity of 9-day-old chick embryo, culturing at 37 deg.C for 3 days, and collecting allantoic fluid.
2. Method of producing a composite material
2.1 grouping and administration
The mice were randomly divided into 9 groups of 12 mice each, normal control group, model control group, 5 example groups (example 1 group, example 2 group, example 3 group, example 4 group and example 5 group), comparative example 1 group and comparative example 2 group, respectively. The test solutions of examples 1 to 5 obtained in 1.1 were used for gastric perfusion in each example, and the comparative example 1 and comparative example 2 were used for comparison obtained in 1.1The solutions to be tested of examples 1 and 2 were gavaged, and were administered continuously for 7 days, once a day, in a volume of 0.2ml/10g of body weight. The normal control group and the model control group were given an equivalent amount of 0.5% CMC-Na. 30 minutes after the mice were dosed on day 3, 50 μ L LD under light ether anesthesia50The virus is dripped into the nose for infection, the normal control group is dripped into the nose by using sterile PBS liquid with the same volume, the mouse is dissected 96 hours after the infection, the lung is taken and weighed, and the lung index is calculated. Taking lung tissue, fixing with formaldehyde, staining by conventional HE, and observing pathological changes of the lung tissue with a light microscope.
2.2 data analysis
The test data adopts SPSS18.0 statistical software, and the results are mean plus or minus standard deviation
Showing that one-way analysis of variance is adopted.
3. Results
3.1 Effect on influenza Virus pulmonary index
The lung index of the model control group was significantly increased (P <0.05) compared to the normal control group, the lung index of the example group and the comparative example group was significantly decreased (P <0.05) compared to the model control group, and the lung index of the example group was lower than that of the comparative example group. See table 8.
TABLE 8 Effect on influenza Virus pulmonary index
Note: comparison with model control group: p < 0.05.
3.2 Effect of the inventive Agents on alterations in Lung tissue pathology
The pathological changes of the lung tissues of the mice are observed under a light microscope, the alveolar cavities of the model control group are full of blood exudates, a large amount of epithelia are shed, and the alveolar wall structure is unclear. The lesions were significantly reduced in the example group and the comparative example group compared to the model group. The lesion range of the example group was more limited than that of the comparative group, the inflammatory cell density was lower, the serous exudation in the alveolar space was less, and the alveolar structure was more intact.
4. Conclusion
The antibacterial and antiviral traditional Chinese medicine composition provided by the embodiment of the invention has an obvious inhibiting effect on mouse influenza virus pneumonia after being administrated in vivo, and is superior to a comparative example.
Effect example 4
The effect example investigates the bacteriostasis effect test of the antibacterial and antiviral traditional Chinese medicine composition on gram-positive bacteria and gram-negative bacteria so as to observe the bacteriostasis of the antibacterial and antiviral traditional Chinese medicine composition.
1. Material
1.1 test drugs
The raw materials and the preparation methods of examples 1 to 5 and comparative examples 1 and 2 were prepared by grinding the raw materials, dissolving the ground raw materials in dimethyl sulfoxide (DMSO) and performing ultrasonic assisted dissolution to obtain a solution with a concentration of 500mg crude drug/ml, and filtering the solution with a 0.22 μm microporous membrane to obtain a solution to be tested.
1.2 test strains
Gram-positive bacteria: staphylococcus aureus (ATCC6538), streptococcus pyogenes (ATCC 19615);
gram-negative bacteria: escherichia coli (ATCC35218) and Pseudomonas aeruginosa (ATCC 9027).
1.3 Medium
Beef extract peptone solid medium: 0.5g of beef extract, 0.5g of sodium chloride, 1.0g of peptone and 100mL of water, and the pH value is 7.0-7.2. Sterilizing at 121 deg.C under 0.1MPa for 20 min;
beef extract peptone liquid medium: 0.5g of beef extract, 0.5g of sodium chloride, 1.0g of peptone, 2.0-4.0 g of agar powder, 100mL of water and pH 7.0-7.2. Sterilizing at 121 deg.C under 0.1MPa for 20 min.
2. Method of producing a composite material
Washing thallus Porphyrae with sterile water from slant culture (24h) of 5 th generation nutrient agar culture medium of the test strain, and diluting with the above beef extract peptone liquid culture medium to obtain extract with concentration of 106cfu/ml bacterial suspension.
The solutions to be tested for each example and comparative example were operated as follows: and (3) taking the sterilized 96-well plate, and adding 100 mu L of beef extract peptone liquid culture medium into the 1 st to 11 th wells respectively. Adding 100 mu L of solution to be tested into the 1 st hole, sucking 100 mu L of the solution to be tested from the 1 st hole and adding the solution to the 2 nd hole after uniform mixing, sucking 100 mu L of the solution to be tested from the 2 nd hole and adding the solution to the 3 rd hole after uniform mixing, performing the operation till the 10 th hole, and finally sucking 100 mu L of the solution to be tested from the 10 th hole and discarding. 100 mu L of bacterial suspension is added into the 1 st to 12 th holes of a 96-well plate. To the 12 th well, 100. mu.L of dimethyl sulfoxide was added as a negative control. Each set was set to 3 parallel tests.
3. Results
The 96-well plate is placed in a constant-temperature incubator at 37 ℃ for 24h, and then is placed under a black background for observation, so that the minimum inhibitory concentration of each sample is obtained, and the results are shown in table 9.
TABLE 9 minimum inhibitory concentrations (in crude drug)
4. Conclusion
The antibacterial and antiviral traditional Chinese medicine composition provided by the embodiment of the invention has an inhibiting effect on both gram-positive bacteria and gram-negative bacteria, and is superior to a comparative example.
Effect example 5
The effect example provides the clinical application effect of the antibacterial and antiviral traditional Chinese medicine composition of example 1.
1. Cases and treatment methods
The clinical application effect of 95 patients with the same symptoms who take the antibacterial and antiviral traditional Chinese medicine composition disclosed by the embodiment 1 in 2018 in 9-2020 in 6 is counted.
The average age of the patients is 38.1 years old (the age range is 20-45 years old), and clinical symptoms are dry stool, one row in a few days, fever, fullness, burning pain of skin, sore throat, thin and yellow tongue coating, red tongue and rapid pulse. The antibacterial and antiviral traditional Chinese medicine composition provided by the embodiment 1 of the invention is taken by each person every day, other medicines are not used in the treatment period, the person does not stay up all night and does not eat spicy food, and 1-2L of water is drunk every day.
2. Therapeutic effects
The clinical symptoms are completely disappeared as a cure standard.
Statistics shows that the dry stool of the patients is obviously relieved or disappears after the patients take the medicine for 1-2 days, the body temperature is reduced, the clinical symptoms disappear after 3-7 days, and the cure rate is 100%. After the medicine is stopped, the daily habits of regular work and rest, no night stay, no spicy food and 1-2L of drinking water every day are kept, and after 1 month, the symptoms are not relapsed.
The results show that the antibacterial and antiviral traditional Chinese medicine composition provided by the invention can effectively eliminate the clinical symptoms of patients caused by internal heat syndrome.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents or improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. An antibacterial antiviral traditional Chinese medicine composition is characterized by comprising the following raw materials in parts by weight: 8-13 parts of fructus forsythiae, 6-12 parts of herba schizonepetae, 12-18 parts of radix isatidis, 7-12 parts of scutellaria baicalensis, 7-12 parts of agastache rugosus, 7-12 parts of gypsum rubrum, 6-11 parts of radix bupleuri, 2-4 parts of rheum officinale, 6-12 parts of fritillaria and 4-8 parts of lucid ganoderma.
2. The antibacterial and antiviral traditional Chinese medicine composition as claimed in claim 1, which is characterized by comprising the following raw materials in parts by weight: 9-12 parts of fructus forsythiae, 7-10 parts of herba schizonepetae, 13-16 parts of radix isatidis, 8-11 parts of scutellaria baicalensis, 8-11 parts of agastache rugosus, 8-11 parts of gypsum rubrum, 7-10 parts of radix bupleuri, 2-4 parts of rheum officinale, 7-10 parts of fritillaria and 5-7 parts of lucid ganoderma.
3. The antibacterial and antiviral traditional Chinese medicine composition as claimed in claim 2, which is characterized by comprising the following raw materials in parts by weight: 10 parts of fructus forsythiae, 9 parts of herba schizonepetae, 15 parts of radix isatidis, 10 parts of scutellaria baicalensis, 9 parts of agastache rugosus, 9 parts of gypsum rubrum, 9 parts of radix bupleuri, 3 parts of rheum officinale, 9 parts of fritillaria and 6 parts of lucid ganoderma.
4. The method for preparing the antibacterial and antiviral traditional Chinese medicine composition as claimed in any one of claims 1 to 3, characterized by comprising the following operations: weighing the raw materials according to the raw material proportion in the antibacterial and antiviral traditional Chinese medicine composition, extracting volatile oil of the wrinkled gianthyssop herb, decocting residues with the weeping forsythia, the fineleaf schizonepeta herb, the indigowoad root, the baical skullcap root, the gypsum rubrum, the Chinese thorowax root, the rhubarb, the fritillaria and the lucid ganoderma in water, extracting, filtering, collecting obtained filtrate, and drying to obtain a water-decocted extract; and adding the volatile oil of the agastache rugosus into the obtained water decoction extract, and uniformly mixing to obtain the antibacterial and antiviral traditional Chinese medicine composition.
5. The use of the antibacterial and antiviral Chinese medicinal composition of any one of claims 1 to 3 in the preparation of a medicament for treating dry stool.
6. The use of the antibacterial and antiviral Chinese medicinal composition of any one of claims 1 to 3 in the preparation of an antipyretic.
7. Use of an antibacterial and antiviral Chinese medicinal composition as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of causalgia.
8. Use of the antibacterial and antiviral traditional Chinese medicine composition of any one of claims 1 to 3 in the preparation of a medicament for treating throat pain.
9. Use of the antibacterial and antiviral Chinese medicinal composition according to any one of claims 1 to 3 in the preparation of a medicament for treating at least two symptoms of dry stool, fever, burning pain of skin and sore throat.
10. An antiviral and/or antibacterial drug, which comprises the antibacterial and antiviral Chinese medicinal composition according to any one of claims 1 to 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010884299.7A CN114099608A (en) | 2020-08-28 | 2020-08-28 | Anti-virus and anti-bacterial traditional Chinese medicine composition containing calcite and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010884299.7A CN114099608A (en) | 2020-08-28 | 2020-08-28 | Anti-virus and anti-bacterial traditional Chinese medicine composition containing calcite and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114099608A true CN114099608A (en) | 2022-03-01 |
Family
ID=80374883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010884299.7A Pending CN114099608A (en) | 2020-08-28 | 2020-08-28 | Anti-virus and anti-bacterial traditional Chinese medicine composition containing calcite and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114099608A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101099787A (en) * | 2007-08-13 | 2008-01-09 | 张文芳 | Traditional Chinese medicinal composition with remarkable wide-spectrum antiviral action |
| CN104189291A (en) * | 2014-09-19 | 2014-12-10 | 周玉娟 | Traditional Chinese medicine composition for treating upper respiratory infection |
-
2020
- 2020-08-28 CN CN202010884299.7A patent/CN114099608A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101099787A (en) * | 2007-08-13 | 2008-01-09 | 张文芳 | Traditional Chinese medicinal composition with remarkable wide-spectrum antiviral action |
| CN104189291A (en) * | 2014-09-19 | 2014-12-10 | 周玉娟 | Traditional Chinese medicine composition for treating upper respiratory infection |
Non-Patent Citations (1)
| Title |
|---|
| 张诗平等: "外感发热的中药治疗动态调查", 中国药房, vol. 10, no. 03, 31 March 1999 (1999-03-31), pages 144 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585433B (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN104523952A (en) | Chinese herbal medicine composition for treating chicken influenza | |
| CN104825960A (en) | Traditional Chinese medicine for treating pulmonary tuberculosis and preparation method thereof | |
| CN102552509A (en) | Traditional Chinese medicine combination for reducing heat and relieving cough | |
| CN114099584A (en) | Antiviral and antibacterial traditional Chinese medicine composition containing houttuynia cordata, and preparation method and application thereof | |
| CN114099608A (en) | Anti-virus and anti-bacterial traditional Chinese medicine composition containing calcite and preparation method and application thereof | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN101209329A (en) | Chinese medicinal oral liquid with heat-clearing and detoxication, lung-heat-clearing and cough-relieving efficacy | |
| CN108524746B (en) | Traditional Chinese medicine composition for preventing and treating poultry cold | |
| CN1872192A (en) | A medication composition,and preparation method | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN114306501A (en) | Antibacterial and antiviral traditional Chinese medicine composition containing fritillaria and preparation method and application thereof | |
| CN1966051A (en) | Antivirus medicament | |
| CN105233063A (en) | Traditional Chinese medicine composition for preventing fowl cholera and preparation method thereof | |
| CN104922530A (en) | Drug combination for preventing and treating chicken colibacillosis and preparing method thereof | |
| CN114306431A (en) | Antibacterial and antiviral traditional Chinese medicine composition containing polygonum cuspidatum and preparation method and application thereof | |
| CN1291730C (en) | Chinese medicine for preventing and treating SARS virus | |
| CN114099591A (en) | Antibacterial and antiviral traditional Chinese medicine composition and preparation method and application thereof | |
| CN114306482A (en) | Antibacterial and antiviral traditional Chinese medicine composition containing bighead atractylodes rhizome as well as preparation method and application thereof | |
| CN114099607A (en) | An antiviral and antibacterial Chinese medicinal composition containing herba Moslae, and its preparation method and application | |
| CN114099605A (en) | Antiviral and antibacterial traditional Chinese medicine composition containing rhizoma dryopteris crassirhizomae and preparation method and application thereof | |
| CN116270896B (en) | Traditional Chinese medicine composition for treating livestock and poultry cough and preparation method thereof | |
| CN115990233B (en) | Traditional Chinese medicine composition for animal mycoplasma pneumonia and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |